Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus- maze

Neuroscience and Biobehavioral Reviews

Volumn 23, Issue 7, 1999, Pages 971-980

  Holmes, A ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Arm confinement; Chlordiazepoxide; Mice; Phobia; Plus maze; Prior experience; Trial duration

Indexed keywords

BENZODIAZEPINE; CHLORDIAZEPOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; EXPERIENCE; MALE; MAZE TEST; MOUSE; NONHUMAN; PHOBIA; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CHLORDIAZEPOXIDE; ENVIRONMENT; EXPLORATORY BEHAVIOR; MALE; MICE; TIME FACTORS;

EID: 0032744697     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(99)00030-5     Document Type: Article

References (51)

1. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmaco Biochem Behav. 54:1996;21-30.
2. Rodgers R.J. Animal models of anxiety: where next? Behav Pharmacol. 8:1997;477-496.
3. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav. 54:1996;31-40.
4. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav. 33:1993;463-469.
5. Pellow S., Chopin P., File S.E., Briley M. Validation of the open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth. 14:1985;149-167.
6. Lister R.G. The use of the plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
7. Handley S.L., Mithani S. Effects of α-adrenoreceptor agonists and antagonists in a maze-exploration model of fear-motivated behaviour. Naunyn-Schmeideberg's Arch Pharmacol. 327:1984;1-5.
8. Cruz A.P.M., Frei F., Graeff F.G. Ethopharmacological analysis of rat behaviour on the elevated plus-maze. Pharmacol Biochem Behav. 49:1994;171-176.
9. Espejo E.F. Structure of mouse behaviour on the elevated plus-maze test of anxiety. Behav Brain Res. 86:1997;105-112.
10. File S.E. Behavioural detection of anxiolytic action. Elliott J.M., Heal D.J., Marsden C.A. Experimental approaches to anxiety and depression. 1992;25-44 Wiley, Chichester.
11. Holmes A., Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? Pharmacol Biochem Behav. 60:1998;473-488.
12. McCreary A.C., McBlane J.W., Spooner H.A., Handley S.L. 5-HT system and anxiety: multiple mechanisms in the elevated X-maze. Pol J Pharmacol. 48:1996;1-12.
13. Rodgers R.J., Johnson J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav. 52:1995;297-303.
14. Rodgers R.J., Cao B., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz J Med Biol Res. 30:1997;289-304.
15. Rodgers R.J., Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. Cooper S.J., Hendrie C.A. Ethology and psychopharmacology. 1994;9-44 Wiley, Chichester.
16. Falter U., Gower A., Gobert J. Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behav Pharmacol. 3:1992;123-128.
17. Grahn R.E., Kalman B.A., Brennan F.X., Watkins L.R., Maier S.F. The elevated plus-maze is not sensitive to the effect of stressor controllability in rats. Pharmacol Biochem Behav. 52:1995;565-570.
18. Pokk P., Zharkovsky A. The effects of drugs acting at GABA-benzodiazepine-barbiturate receptor complex on the behaviour of sleep deprived mice. Pharmacol Toxicol. 76:1995;23-28.
19. File S.E., Mabbutt P.S., Hitchcott P.K. Characterisation of the phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology. 102:1990;98-101.
20. Almeida S.S., Garcia R.A., De Oliviera L.M. Effects of early protein malnutrition and repeated testing upon locomotor and exploratory behaviors in the elevated plus-maze. Physiol Behav. 54:1993;749-752.
21. Dawson G.R., Crawford S.P., Stanhope K.J., Iversen S.D., Tricklebank M.D. One-trial tolerance to the effects of chlordiazepoxide on the elevated plus-maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology. 113:1994;570-572.
22. Espejo E.F. Effects of weekly or daily exposure to the elevated plus-maze in male mice. Behav Brain Res. 87:1997;233-238.
23. Gonzalez L.E., File S.E. A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphé nucleus. J Neurosci. 15:1997;1505-1511.
24. Griebel G., Moreau J.L., Jenck F., Martin J.R., Misslin R. Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav Proc. 29:1993;37-48.
25. Lee C., Rodgers R.J. Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology. 102:1990;507-513.
26. Rodgers R.J., Lee C., Shepherd J.K. Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology. 106:1992;102-110.
27. Rodgers R.J., Johnson N.J.T., Carr J., Hodgson T.P. Resistance of experientially induced changes in murine plus-maze behaviour to altered retest conditions. Behav Brain Res. 86:1997;71-77.
28. Rodgers R.J., Johnson J.T., Cole J.C., Dewar C.V., Kidd G.R., Kimpson P.H. Plus-maze retest profile in mice: Importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade. Pharmacol Biochem Behav. 54:1996;41-50.
29. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and the light/dark tests of anxiety in mice. Psychopharmacology. 113:1993;237-242.
30. Schmitt U., Hiemke C. Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. Pharmacol Biochem Behav. 59:1998;807-811.
31. Shepherd JK. Preliminary evaluation of an elevated zero-maze as a model of anxiety in laboratory rats. Paper delivered to a Joint meeting of the British Association for Psychopharmacology and the European Behavioural Pharmacology Society, Cambridge, August 1992.
32. File S.E., Zangrossi H., Sanders F.L., Mabbutt P.S. Raised corticosterone in the rat after exposure to the elevated plus maze. Psychopharmacology. 113:1994;543-546.
33. Holmes A., Diffley E.P., Walton T.J., Brain P.F., Rodgers R.J. Lack of habituation of corticosterone response in mice repeatedly exposed to the plus-maze. J Psychopharmacology. 12S:1998;32.
34. File S.E. The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res. 58:1993;199-202.
35. File S.E., Zangrossi H., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology. 111:1993;491-494.
36. File S.E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology. 100:1990;281-282.
37. File S.E., Zangrossi H.J. One-trial tolerance to the anxiolytic actions of the benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology. 110:1993;240-244.
38. Nutt D.J. The pharmacology of human anxiety. Pharmac Ther. 47:1990;233-266.
39. Tancer M.E., Uhde T.W. Social phobia: a review of pharmacological treatments. CNS Drugs. 3:1995;267-278.
40. Almeida S.S., DeOliveira L.M., Graeff F.G. Early life protein malnutrition changes exploration in the elevated plus-maze and reactivity to anxiolytics. Psychopharmacology. 103:1991;513-518.
41. Critchley M.A.E., Handley S.L. Effects in the X-maze anxiety model if agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology. 93:1987;502-506.
42. Itoh J., Nabeshima T., Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology. 101:1990;27-33.
43. Rodgers R.J., Cole J.C. An ethological analysis of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behav Pharmacol. 4:1993;573-580.
44. Weiss SM. Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny Owl. PhD thesis, University of Leeds, 1995.
45. Adamec R.E., Shallow T. Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav. 54:1993;101-109.
46. Lapin I.P. Only controls: effect of handling, sham injection, and intraperitoneal injection of saline on behavior of mice in an elevated plus-maze. J Pharmacol Toxicol Meth. 34:1995;73-77.
47. Saldívar-Gonzalez A., Arias C., Mondragón-Ceballos R. Transient emotional changes elicited by intraperitoneal saline injection: effect of naloxone and flumazenil. Pharmacol Biochem Behav. 56:1997;211-220.
48. Halliday M.S. Exploratory behaviour in elevated and enclosed mazes. Q J Exp Psychol. 19:1967;254-263.
49. Lester D. Effects of habituation to fear on the exploratory behaviour of rats. Nature. 220:1968;932.
50. Lester D. Two tests of a fear-motivated theory of exploration. Psychonomic Sci. 10:1968;385-386.
51. Copland A.M., Balfour D.J.K. Spontaneous activity and brain 5-hyroxyindole levels measured in rats tested in two designs of elevated X-maze. Life Sci. 41:1987;57-64.